Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio

WLJ Van Putten, MG Manz, MC Vekemans… - Leukemia, 2017 - nature.com
Post-remission treatment (PRT) in patients with cytogenetically normal (CN) acute myeloid
leukemia (AML) in first complete remission (CR1) is debated. We studied 521 patients with …
被引用次数：64 相关文章

Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio.

J Versluis, R Devillier, WLJ van Putten, MG Manz… - Leukemia, 2017 - go.gale.com
Post-remission treatment (PRT) in patients with cytogenetically normal (CN) acute myeloid
leukemia (AML) in first complete remission (CR1) is debated. We studied 521 patients with …

Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio.

J Versluis, FEM In't Hout, R Devillier, WLJ van Putten… - Leukemia, 2017 - orbi.uliege.be
Post-remission treatment (PRT) in patients with cytogenetically normal (CN) acute myeloid
leukemia (AML) in first complete remission (CR1) is debated. We studied 521 patients with …

[引用][C] Comparative Value of Post-Remission Treatment in Cytogenetically Normal AML Subclassified by NPM1 and FLT3-ITD Allelic Ratio

J Versluis, R Devillier… - Clinical …, 2016 - clinical-lymphoma-myeloma …
Objective Outcome of different PRTs was compared by time-dependent analysis in patients
with CN-AML in CR1, according to molecular subtype.

Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio

J Versluis, FE In't Hout, R Devillier, WL van Putten… - Leukemia, 2016 - zora.uzh.ch
Post-remission treatment (PRT) in patients with cytogenetically normal (CN) acute myeloid
leukemia (AML) in first complete remission (CR1) is debated. We studied 521 patients with …

Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio

J Versluis, FEM In't Hout, R Devillier… - …, 2017 - cris.maastrichtuniversity.nl
Post-remission treatment (PRT) in patients with cytogenetically normal (CN) acute myeloid
leukemia (AML) in first complete remission (CR1) is debated. We studied 521 patients with …

Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio.

J Versluis, FEM In't Hout, R Devillier, WLJ van Putten… - Leukemia, 2017 - boris.unibe.ch
Post-remission treatment (PRT) in patients with cytogenetically normal (CN) acute myeloid
leukemia (AML) in first complete remission (CR1) is debated. We studied 521 patients with …

Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio

J Versluis, FEM In't Hout, R Devillier… - …, 2017 - pubmed.ncbi.nlm.nih.gov
Post-remission treatment (PRT) in patients with cytogenetically normal (CN) acute myeloid
leukemia (AML) in first complete remission (CR1) is debated. We studied 521 patients with …

Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio

J Versluis, FEMIT Hout, R Devillier… - …, 2017 - researchinformation.amsterdamumc …
Post-remission treatment (PRT) in patients with cytogenetically normal (CN) acute myeloid
leukemia (AML) in first complete remission (CR1) is debated. We studied 521 patients with …

Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio

J Versluis, FEM In'T Hout, R Devillier, W van Putten… - Leukemia, 2017 - repub.eur.nl
Post-remission treatment (PRT) in patients with cytogenetically normal (CN) acute myeloid
leukemia (AML) in first complete remission (CR1) is debated. We studied 521 patients with …